Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6219) 6219
Book Review (1656) 1656
Publication (456) 456
Newsletter (234) 234
Newspaper Article (150) 150
Book Chapter (70) 70
Book / eBook (57) 57
Conference Proceeding (28) 28
Dissertation (10) 10
Trade Publication Article (5) 5
Magazine Article (4) 4
Web Resource (4) 4
Transcript (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5166) 5166
humans (4952) 4952
female (3069) 3069
male (3001) 3001
middle aged (2770) 2770
oncology (2712) 2712
lymphomas (2457) 2457
adult (2440) 2440
aged (2400) 2400
hematology (2294) 2294
cancer (1593) 1593
prognosis (1581) 1581
lymphoma (1492) 1492
non-hodgkins-lymphoma (1402) 1402
chemotherapy (1360) 1360
aged, 80 and over (1109) 1109
treatment outcome (1108) 1108
rituximab (1104) 1104
antineoplastic combined chemotherapy protocols - therapeutic use (1007) 1007
follicular lymphoma (960) 960
care and treatment (952) 952
transplantation (886) 886
retrospective studies (831) 831
disease-free survival (803) 803
survival rate (792) 792
adolescent (791) 791
non-hodgkin's lymphomas (783) 783
survival (783) 783
b-cell lymphoma (770) 770
research (748) 748
risk factors (711) 711
survival analysis (708) 708
lymphoma, follicular - mortality (672) 672
neoplasm staging (668) 668
leukemia (620) 620
young adult (620) 620
lymphoma, non-hodgkin - mortality (609) 609
health aspects (606) 606
analysis (597) 597
therapy (585) 585
immunology (583) 583
medicine & public health (568) 568
follow-up studies (540) 540
stem cells (531) 531
diagnosis (503) 503
mortality (503) 503
abridged index medicus (474) 474
antineoplastic agents - therapeutic use (468) 468
chronic lymphocytic-leukemia (465) 465
combined modality therapy (451) 451
pathology (451) 451
lymphoma, large b-cell, diffuse - mortality (449) 449
bone-marrow-transplantation (436) 436
patients (431) 431
animals (428) 428
disease (422) 422
non-hodgkin lymphoma (420) 420
lymphoma, follicular - drug therapy (413) 413
hematology, oncology and palliative medicine (409) 409
hemic and lymphatic diseases (408) 408
lymphoma, non-hodgkin - drug therapy (408) 408
lymphoma, non-hodgkin - pathology (401) 401
immunotherapy (397) 397
lymphoma, non-hodgkin - therapy (394) 394
tumors (387) 387
non-hodgkin's lymphoma (377) 377
recurrence (377) 377
lymphoma, follicular - pathology (374) 374
cyclophosphamide - administration & dosage (371) 371
patient outcomes (355) 355
medical research (348) 348
child (347) 347
risk (346) 346
epidemiology (345) 345
transplantation, autologous (338) 338
classification (335) 335
stem-cell transplantation (333) 333
expression (331) 331
non-hodgkin-lymphoma (329) 329
antineoplastic combined chemotherapy protocols - administration & dosage (326) 326
cyclophosphamide (325) 325
lymphoma, follicular - therapy (322) 322
immunohistochemistry (319) 319
kaplan-meier estimate (316) 316
antibodies, monoclonal - therapeutic use (315) 315
antineoplastic combined chemotherapy protocols - adverse effects (312) 312
t cells (309) 309
article (308) 308
radiotherapy (301) 301
lymphoma - mortality (293) 293
lymphoma, large b-cell, diffuse - pathology (291) 291
hematopoietic stem cells (288) 288
remission induction (284) 284
incidence (283) 283
time factors (281) 281
hematopoietic stem cell transplantation (279) 279
lymphocytes (276) 276
antibodies, monoclonal, murine-derived (273) 273
lymphoma, large b-cell, diffuse - drug therapy (273) 273
vincristine - administration & dosage (268) 268
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (46) 46
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT Schools - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6656) 6656
German (24) 24
Japanese (23) 23
Spanish (13) 13
French (11) 11
Chinese (4) 4
Russian (4) 4
Czech (3) 3
Polish (3) 3
Portuguese (3) 3
Hungarian (2) 2
Danish (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Follicular lymphoma international prognostic index
by Solal-Céligny, Philippe and Roy, Pascal and Colombat, Philippe and White, Josephine and Armitage, Jim O and Arranz-Saez, Reyes and Au, Wing Y and Bellei, Monica and Brice, Pauline and Caballero, Dolores and Coiffier, Bertrand and Conde-Garcia, Eulogio and Doyen, Chantal and Federico, Massimo and Fisher, Richard I and Garcia-Conde, Javier F and Guglielmi, Cesare and Hagenbeek, Anton and Haïoun, Corinne and LeBlanc, Michael and Lister, Anew T and Lopez-Guillermo, Armando and McLaughlin, Peter and Milpied, Noël and Morel, Pierre and Mounier, Nicolas and Proctor, Stephen J and Rohatiner, Ama and Smith, Paul and Soubeyran, Pierre and Tilly, Hervé and Vitolo, Umberto and Zinzani, Pier-Luigi and Zucca, Emanuele and Montserrat, Emili
Blood, ISSN 0006-4971, 2004, Volume 104, Issue 5, pp. 1258 - 1265
The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help in evaluating... 
LOW-GRADE LYMPHOMA | B-CELL LYMPHOMA | ANTI-CD20 MONOCLONAL-ANTIBODY | AGGRESSIVE LYMPHOMAS | STAGE | NON-HODGKINS-LYMPHOMA | PREDICTIVE MODEL | MULTIVARIATE-ANALYSIS | IDENTIFICATION | HEMATOLOGY | DETUDE DES LYMPHOMES | Multivariate Analysis | Lymphoma, Follicular - therapy | Age Distribution | Prognosis | Humans | Middle Aged | Risk Factors | Lymphoma, Follicular - mortality | Male | Survival Analysis | Adult | Female | Aged | Index Medicus | Abridged Index Medicus | Life Sciences | Other
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
by Marcus, Robert and Davies, Andrew and Ando, Kiyoshi and Klapper, Wolfram and Opat, Stephen and Owen, Carolyn and Phillips, Elizabeth and Sangha, Randeep and Schlag, Rudolf and Seymour, John F and Townsend, William and Trněný, Marek and Wenger, Michael and Fingerle-Rowson, Günter and Rufibach, Kaspar and Moore, Tom and Herold, Michael and Hiddemann, Wolfgang
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1331 - 1344
Obinutuzumab is an anti-CD20 antibody engineered to elicit killing mechanisms distinct from rituximab. In a trial of chemotherapy plus obinutuzumab or... 
MAINTENANCE | MEDICINE, GENERAL & INTERNAL | PREDNISONE | INTERFERON | CYCLOPHOSPHAMIDE | RITUXIMAB | VINCRISTINE | DOXORUBICIN | CHLORAMBUCIL | CHEMOTHERAPY | GA101 | Antibodies, Monoclonal, Humanized - adverse effects | Lymphoma, Follicular - drug therapy | Nausea - chemically induced | Humans | Middle Aged | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Lymphoma, Follicular - mortality | Induction Chemotherapy | Male | Antineoplastic Agents - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Aged | Immunologic Factors - adverse effects | Rituximab - adverse effects | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Lymphomas | Drug therapy | Observations | Methods | Medical research | Gallium | Rituximab | Cytotoxicity | Nausea | Lymphoma | Cancer therapies | Survival | Studies | Chemotherapy | CD20 antigen | Death | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study
by Casulo, Carla and Byrtek, Michelle and Dawson, Keith L and Zhou, Xiaolei and Farber, Charles M and Flowers, Christopher R and Hainsworth, John D and Maurer, Matthew J and Cerhan, James R and Link, Brian K and Zelenetz, Andrew D and Friedberg, Jonathan W
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 23, pp. 2516 - 2522
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy. We... 
UNITED-STATES | 1ST-LINE TREATMENT | ONCOLOGY | FREE SURVIVAL | END-POINT | PHASE-III | NON-HODGKINS-LYMPHOMA | RANDOMIZED-TRIAL | R-CVP | STEM-CELL TRANSPLANTATION | WORKING PARTY | United States - epidemiology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Time Factors | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Lymphoma, Follicular - mortality | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Index Medicus | ORIGINAL REPORTS | Hema14
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource
by Link, Brian K and Link, Brian K and Maurer, Matthew J and Maurer, Matthew J and Nowakowski, Grzegorz S and Nowakowski, Grzegorz S and Ansell, Stephen M and Ansell, Stephen M and Macon, William R and MacOn, William R and Syrbu, Sergei I and Syrbu, Sergei I and Slager, Susan L and Slager, Susan L and Thompson, Carrie A and Thompson, Carrie A and Inwards, David J and Inwards, David J and Johnston, Patrick B and Johnston, Patrick B and Colgan, Joseph P and Colgan, Joseph P and Witzig, Thomas E and Witzig, Thomas E and Habermann, Thomas M and Habermann, Thomas M and Cerhan, James R and Cerhan, James R
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 26, pp. 3272 - 3278
This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun... 
L-Lactate Dehydrogenase - metabolism | Lymphoma, Follicular - drug therapy | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Young Adult | Neoplasm Grading | Aged, 80 and over | Adult | Female | Lymphoma, Follicular - pathology | Risk Factors | Lymphoma, Follicular - mortality | Rituximab | Survival Rate | Cell Transformation, Neoplastic - immunology | Molecular Epidemiology | Aged | Cell Transformation, Neoplastic - drug effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Number of CD4+ Cells and Location of Forkhead Box Protein P3–Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome
by Abigail M. Lee and Andrew J. Clear and Maria Calaminici and Andrew J. Davies and Suzanne Jordan and Finlay MacDougall and Janet Matthews and Andrew J. Norton and John G. Gribben and T. Andrew Lister and Lindsey K. Goff
Journal of Clinical Oncology, ISSN 0732-183X, 11/2006, Volume 24, Issue 31, pp. 5052 - 5059
Purpose To examine the immune microenvironment in diagnostic follicular lymphoma (FL) biopsies and evaluate its prognostic significance. Patients and Methods... 
HODGKINS LYMPHOMA | SURVIVAL | TRANSFORMATION | IMMUNE-RESPONSE | ONCOLOGY | KINETICS | VACCINE | REGULATORY T-CELLS | EXPRESSION | CARCINOMA | Immunohistochemistry | Lymphoma, Follicular - chemistry | Humans | Forkhead Transcription Factors - analysis | Survival Analysis | Lymphoma, Follicular - mortality | Protein Array Analysis | CD4-Positive T-Lymphocytes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ocular Adnexal Follicular Lymphoma: A Multicenter International Study
by Rasmussen, Peter K and Coupland, Sarah E and Finger, Paul T and Graue, Gerardo F and Grossniklaus, Hans E and Honavar, Santosh G and McKelvie, Penny and Mulay, Kaustubh and Prause, Jan U and Ralfkiaer, Elisabeth and Sjö, Lene D and Heegaard, Steffen
JAMA Ophthalmology, ISSN 2168-6165, 07/2014, Volume 132, Issue 7, pp. 851 - 858
IMPORTANCE: The clinical features of the follicular subtype of ocular adnexal lymphoma (OAL) have not been previously evaluated in a large cohort. OBJECTIVE:... 
PROGNOSTIC-FACTORS | MALIGNANT-LYMPHOMA | SUBTYPES | EARLY-STAGE | OPHTHALMOLOGY | CLASSIFICATION | COMMITTEE | SALIVARY-GLAND LYMPHOMA | EPIDEMIOLOGY | RADIATION-THERAPY | FEATURES | Eyelid Neoplasms - diagnosis | Lymphoma, Follicular - therapy | Humans | Middle Aged | Lymphoma, Follicular - diagnosis | Male | Antineoplastic Agents - therapeutic use | Lacrimal Apparatus Diseases - therapy | Eye Neoplasms - therapy | Orbital Neoplasms - therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Biomarkers, Tumor - analysis | Lymphoma, Follicular - mortality | Survival Rate | Combined Modality Therapy | Conjunctival Neoplasms - therapy | Eyelid Neoplasms - therapy | Disease-Free Survival | Eye Neoplasms - diagnosis | Lacrimal Apparatus Diseases - mortality | Eye Neoplasms - mortality | Lacrimal Apparatus Diseases - diagnosis | Proton Therapy | Biopsy | Internationality | Conjunctival Neoplasms - mortality | Orbital Neoplasms - diagnosis | Neoplasm Proteins - analysis | Aged | Orbital Neoplasms - mortality | Neoplasm Staging | Eyelid Neoplasms - mortality | Cohort Studies | Conjunctival Neoplasms - diagnosis | Eye | Care and treatment | Causes of | Lymphomas | Diagnosis | Research | Movement disorders | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
by Westin, Jason R, MD and Chu, Fuliang, PhD and Zhang, Min, PhD and Fayad, Luis E, MD and Kwak, Larry W, Prof and Fowler, Nathan, MD and Romaguera, Jorge, Prof and Hagemeister, Fredrick, Prof and Fanale, Michelle, MD and Samaniego, Felipe, MD and Feng, Lei, MS and Baladandayuthapani, Veerabhadran, PhD and Wang, Zhiqiang, PhD and Ma, Wencai, PhD and Gao, Yanli, MS and Wallace, Michael, Prof and Vence, Luis M, PhD and Radvanyi, Laszlo, Prof and Muzzafar, Tariq, MD and Rotem-Yehudar, Rinat, PhD and Davis, R Eric, MD and Neelapu, Sattva S, Dr
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 69 - 77
Summary Background Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | NON-HODGKINS-LYMPHOMA | II TRIAL | MODEL | MONOCLONAL-ANTIBODY THERAPY | T-CELL EXHAUSTION | CANCER | EXPRESSION | PD-1 | TUMOR MICROENVIRONMENT | Recurrence | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - mortality | Rituximab | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Antimitotic agents | Care and treatment | Relapse | Monoclonal antibodies | Lymphomas | Product development | Antineoplastic agents | T cells | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
by Maurer, Matthew J and Bachy, Emmanuel and Ghesquières, Hervé and Ansell, Stephen M and Nowakowski, Grzegorz S and Thompson, Carrie A and Inwards, David J and Allmer, Cristine and Chassagne‐Clément, Catherine and Nicolas‐Virelizier, Emmanuelle and Sebban, Catherine and Lebras, Laure and Sarkozy, Clementine and Macon, William R and Feldman, Andrew L and Syrbu, Sergei I and Traverse‐Glehan, Alexandra and Coiffier, Bertrand and Slager, Susan L and Weiner, George J and Witzig, Thomas E and Habermann, Thomas M and Salles, Gilles and Cerhan, James R and Link, Brian K
American Journal of Hematology, ISSN 0361-8609, 11/2016, Volume 91, Issue 11, pp. 1096 - 1101
Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event‐free... 
B-CELL LYMPHOMA | NATIONAL LYMPHOCARE | INTERNATIONAL PROGNOSTIC INDEX | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | VINCRISTINE | NON-HODGKINS-LYMPHOMA | UNIVERSITY | HEMATOLOGY | CHEMOTHERAPY | Prognosis | Humans | Middle Aged | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Male | Treatment Outcome | Young Adult | Disease-Free Survival | Lymphoma, Follicular - epidemiology | Immunotherapy | Survival Analysis | Aged, 80 and over | Adult | Female | Registries | Aged | Early Diagnosis | Lymphomas | Epidemiology | Conferences and conventions | Mortality | Index Medicus | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
by Ardeshna, Kirit M, Dr and Qian, Wendi, PhD and Smith, Paul, MSc and Braganca, Nivette, MSc and Lowry, Lisa, FRCPath and Patrick, Pip, PhD and Warden, June, MSc and Stevens, Lindsey and Pocock, Christopher F E, PhD and Miall, Fiona, MD and Cunningham, David, Prof and Davies, John, FRCP and Jack, Andrew, FRCP and Stephens, Richard, MA and Walewski, Jan, MD and Ferhanoglu, Burhan, Prof and Bradstock, Ken, Prof and Linch, David C, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 424 - 435
Summary Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchful waiting until disease... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | POLICY | THERAPY | ONCOLOGY | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Asymptomatic Diseases | Patient Selection | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Lymphoma, Follicular - pathology | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Lymphoma, Follicular - mortality | Rituximab | Treatment Outcome | Disease Progression | New Zealand | Disease-Free Survival | Intention to Treat Analysis | Quality of Life | Watchful Waiting | Aged | Australia | Neoplasm Staging | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Clinical trials | Care and treatment | Chemotherapy | Tumors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
by Tzankov, Alexandar and Meier, Cecile and Hirschmann, Petra and Went, Philip and Pileri, Stefano A and Dirnhofer, Stephan
Haematologica, ISSN 0390-6078, 02/2008, Volume 93, Issue 2, pp. 193 - 200
1 Institute of Pathology, University Hospital Basel, Switzerland; 2 Institute of Pathology, Triemli Hospital, Zurich, Switzerland; 3 Chair of Pathology and... 
Receiver operating characteristic curves | Tissue microarray | FOXP3 | Lymphoma | Treg | ACTIVATION | tissue microarray | receiver operating characteristic curves | lymphoma | PHENOTYPE | SUPPRESSION | ACT | TRANSCRIPTION FACTOR FOXP3 | RARE EXPRESSION | HEMATOLOGY | LYMPHOCYTES | Forkhead Transcription Factors - immunology | Immunohistochemistry | Age Factors | Hodgkin Disease - pathology | Cell Count | Germinal Center - immunology | Humans | Middle Aged | Male | T-Lymphocytes, Regulatory - pathology | T-Lymphocytes, Regulatory - immunology | Microarray Analysis | Lymphoma, B-Cell - immunology | Hodgkin Disease - mortality | Adult | Female | Retrospective Studies | Lymphoma, B-Cell - mortality | Lymphoma, Follicular - pathology | Lymphoma, Follicular - mortality | Survival Rate | Germinal Center - pathology | Disease-Free Survival | Lymphoma, Follicular - immunology | Adolescent | Lymphoma, B-Cell - pathology | Hodgkin Disease - immunology | Aged | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
by Vidal, Liat and Gafter-Gvili, Anat and Salles, Gilles and Bousseta, Sami and Oberman, Bernice and Rubin, Carmit and van Oers, Marinus H.J and Fortpied, Catherine and Ghielmini, Michele and Pettengell, Ruth and Witzens-Harig, Mathias and Dreger, Peter and Vitolo, Umberto and Gomes da Silva, Maria and Evangelista, Andrea and Li, Hailun and Freedman, Laurence and Habermann, Thomas M and Shpilberg, Ofer
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, Issue 17, pp. 216 - 225
Abstract Background Randomised trials of rituximab maintenance (MR) for patients with follicular lymphoma support improved progression-free survival (PFS), but... 
Hematology, Oncology and Palliative Medicine | Follicular lymphoma | Rituximab | Maintenance | Meta-analysis | MULTICENTER | ONCOLOGY | OPEN-LABEL | PHASE-3 | INDOLENT | Immunocompromised Host - immunology | Doxorubicin - therapeutic use | Multivariate Analysis | Cyclophosphamide - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Induction Chemotherapy | Male | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Infection - etiology | Young Adult | Rituximab - therapeutic use | Infection - epidemiology | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Maintenance Chemotherapy | Prednisone - administration & dosage | Proportional Hazards Models | Lymphoma, Follicular - mortality | Survival Rate | Randomized Controlled Trials as Topic | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Aged | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Medical policy | Patient outcomes | Analysis | Oncology, Experimental | Lymphomas | Research | Epidemiology | Cancer | Therapy | Data analysis | Clinical trials | Data processing | Infections | Lymphoma | Patients | Survival | Subgroups | Randomization | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
by Casulo, Carla and Friedberg, Jonathan W and Ahn, Kwang W and Flowers, Christopher and DiGilio, Alyssa and Smith, Sonali M and Ahmed, Sairah and Inwards, David and Aljurf, Mahmoud and Chen, Andy I and Choe, Hannah and Cohen, Jonathon and Copelan, Edward and Farooq, Umar and Fenske, Timothy S and Freytes, Cesar and Gaballa, Sameh and Ganguly, Siddhartha and Jethava, Yogesh and Kamble, Rammurti T and Kenkre, Vaishalee P and Lazarus, Hillard and Lazaryan, Aleksandr and Olsson, Richard F and Rezvani, Andrew R and Rizzieri, David and Seo, Sachiko and Shah, Nina and Shah, Gunjan L and Solh, Melham and Sureda, Anna and William, Basem and Cumpston, Aaron and Zelenetz, Andrew D and Link, Brian K and Hamadani, Mehdi and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Centrum för klinisk forskning i Sörmland (CKFD)
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 06/2018, Volume 24, Issue 6, pp. 1163 - 1171
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS).... 
Follicular lymphoma | Rituximab | Early therapy failure | Autologous transplantation | Chemoimmunotherapy | Early transplant | BENDAMUSTINE | 1ST-LINE TREATMENT | MODERN-ERA | RANDOMIZED-TRIAL | RISK | OPEN-LABEL | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | NON-HODGKIN-LYMPHOMA | STEM-CELL TRANSPLANTATION | CHOP PLUS RITUXIMAB | HEMATOLOGY | Lymphoma, Follicular - therapy | Transplantation, Autologous - mortality | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Secondary Prevention | Hematopoietic Stem Cell Transplantation - mortality | Young Adult | Rituximab - therapeutic use | Graft Rejection - mortality | Survival Analysis | Adult | Female | Antimitotic agents | Autografts | Medical research | Care and treatment | Analysis | Medicine, Experimental | Bone marrow | Lymphomas | Transplantation | Antineoplastic agents | Cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States
by Nabhan, Chadi and Byrtek, Michelle and Rai, Ashish and Dawson, Keith and Zhou, Xiaolei and Link, Brian K and Friedberg, Jonathan W and Zelenetz, Andrew D and Maurer, Matthew J and Cerhan, James R and Flowers, Christopher R
British Journal of Haematology, ISSN 0007-1048, 07/2015, Volume 170, Issue 1, pp. 85 - 95
Data from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma ( FL ) patients from 2004 to 2007) were used to... 
elderly patients | follicular lymphoma | elderly lymphoma | chemotherapy | rituximab | Follicular lymphoma | Rituximab | Elderly lymphoma | Chemotherapy | Elderly patients | SURVIVAL | CYCLOPHOSPHAMIDE | SEX | CANCER | PREDNISONE | IMPACT | NATIONAL LYMPHOCARE | VINCRISTINE | INDEX | HEMATOLOGY | United States - epidemiology | Lymphoma, Follicular - therapy | Prognosis | Prospective Studies | Lymphoma, Follicular - pathology | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Treatment Outcome | Young Adult | Disease-Free Survival | Lymphoma, Follicular - epidemiology | Aged, 80 and over | Adult | Female | Aged | Cohort Studies | Analysis | Mortality | Lymphomas | Health aspects | Epidemiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights